The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
暂无分享,去创建一个
John T. Chang | Shuang Wang | Xiaoqian Jiang | Siddharth Singh | B. Sands | C. Siegel | W. Sandborn | E. Loftus | P. Dulai | B. Boland | J. Colombel | A. Swaminath | S. Kane | D. Hudesman | D. Lukin | N. Narula | K. Chaudrey | E. Shmidt | D. Whitehead | F. Peerani | John T. Chang
[1] S. Schreiber,et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study , 2016, Alimentary pharmacology & therapeutics.
[2] Siddharth Singh,et al. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.
[3] A. Ford,et al. Systematic review with meta‐analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease , 2016, Alimentary pharmacology & therapeutics.
[4] Chien-Huan Chen,et al. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. , 2016, Journal of Crohn's & colitis.
[5] M. Silverberg,et al. A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables , 2016, Alimentary pharmacology & therapeutics.
[6] N. Ding,et al. Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.
[7] A. Ananthakrishnan,et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort , 2015, Inflammatory bowel diseases.
[8] W. Sandborn,et al. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s Disease , 2015, The American Journal of Gastroenterology.
[9] S. Vermeire,et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials , 2015, Gut.
[10] G. D'Haens,et al. Assessment of mucosal healing in inflammatory bowel disease: review. , 2015, Gastrointestinal endoscopy.
[11] J. Gisbert,et al. Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed , 2015, Alimentary pharmacology & therapeutics.
[12] G. Kaplan,et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. , 2015, Gastroenterology.
[13] Zhen Wang,et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis. , 2014, Mayo Clinic proceedings.
[14] S. Danese,et al. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. , 2014, Gastroenterology.
[15] Heather B. Blunt,et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] P. Rutgeerts,et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.
[17] C. Siegel,et al. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. , 2014, Gastroenterology clinics of North America.
[18] C. Siegel,et al. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD , 2014, Gut.
[19] O. Dewit,et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] P. Rutgeerts,et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial , 2013, Gut.
[21] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[22] P. Rutgeerts,et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.
[23] D. Hommes,et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. , 2013, Journal of Crohn's & colitis.
[24] G. Corazza,et al. Effect of Tumor Necrosis Factor-&agr; Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease , 2013, Inflammatory bowel diseases.
[25] A. Kornbluth,et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] H. Sokol,et al. Current smoking differentially affects blood mononuclear cells from patients with crohn's disease and ulcerative colitis: Relevance to its adverse role in the disease , 2012, Inflammatory bowel diseases.
[27] P. Rutgeerts,et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.
[28] M. Gazouli,et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. , 2010, Journal of Crohn's & colitis.
[29] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[30] S. Pocock,et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.
[31] J. Satsangi,et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.
[32] I. Hauser,et al. Differential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion. , 1993, Journal of immunology.
[33] Erik von Elm,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.